Literature DB >> 26155432

Regramming myeloid responses to improve cancer immunotherapy.

Yu Zhu1, William G Hawkins2, David G DeNardo3.   

Abstract

Infiltration by immunosuppressive myeloid cells helps tumors to overcome immune surveillance and can render patients less responsive to therapeutic intervention. Several recent studies have demonstrated that reprogramming myeloid responses can effectively enhance cancer immunotherapy, suggesting several new potential combination therapies for clinical testing.

Entities:  

Keywords:  MDSCs; PD-1; cancer immunotherapy; immune checkpoints; macrophages

Year:  2015        PMID： 26155432      PMCID： PMC4492504          DOI： 10.4161/2162402X.2014.974399

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Macrophage diversity enhances tumor progression and metastasis.

Authors:  Bin-Zhi Qian; Jeffrey W Pollard
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

3.  Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

Authors:  Steven L Highfill; Yongzhi Cui; Amber J Giles; Jillian P Smith; Hua Zhang; Elizabeth Morse; Rosandra N Kaplan; Crystal L Mackall
Journal:  Sci Transl Med       Date:  2014-05-21       Impact factor: 17.956

4.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

5.  Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

Authors:  Richard E Royal; Catherine Levy; Keli Turner; Aarti Mathur; Marybeth Hughes; Udai S Kammula; Richard M Sherry; Suzanne L Topalian; James C Yang; Israel Lowy; Steven A Rosenberg
Journal:  J Immunother       Date:  2010-10       Impact factor: 4.456

Review 6.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

7.  Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.

Authors:  Stephen Mok; Richard C Koya; Christopher Tsui; Jingying Xu; Lídia Robert; Lily Wu; Thomas Graeber; Brian L West; Gideon Bollag; Antoni Ribas
Journal:  Cancer Res       Date:  2013-11-18       Impact factor: 12.701

Review 8.  Myeloid-derived suppressor cells as regulators of the immune system.

Authors:  Dmitry I Gabrilovich; Srinivas Nagaraj
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

9.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

Authors:  Yu Zhu; Brett L Knolhoff; Melissa A Meyer; Timothy M Nywening; Brian L West; Jingqin Luo; Andrea Wang-Gillam; S Peter Goedegebuure; David C Linehan; David G DeNardo
Journal:  Cancer Res       Date:  2014-07-31       Impact factor: 12.701

10.  Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer.

Authors:  S A Quezada; K S Peggs
Journal:  Br J Cancer       Date:  2013-03-19       Impact factor: 7.640
  10 in total
  4 in total

Review 1.  High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.

Authors:  Suresh Gopi Kalathil; Yasmin Thanavala
Journal:  Cancer Immunol Immunother       Date:  2016-02-24       Impact factor: 6.968

2.  Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers.

Authors:  Edurne Mugarza; Febe van Maldegem; Jesse Boumelha; Christopher Moore; Sareena Rana; Miriam Llorian Sopena; Philip East; Rachel Ambler; Panayiotis Anastasiou; Pablo Romero-Clavijo; Karishma Valand; Megan Cole; Miriam Molina-Arcas; Julian Downward
Journal:  Sci Adv       Date:  2022-07-20       Impact factor: 14.957

Review 3.  Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

Authors:  Andrew M Bellinger; Carlos L Arteaga; Thomas Force; Benjamin D Humphreys; George D Demetri; Brian J Druker; Javid J Moslehi
Journal:  Circulation       Date:  2015-12-08       Impact factor: 29.690

4.  Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer.

Authors:  Jessica Nakhlé; Valérie Pierron; Anne-Laure Bauchet; Pascale Plas; Amath Thiongane; Florence Meyer-Losic; Fabien Schmidlin
Journal:  Oncoimmunology       Date:  2016-02-18       Impact factor: 8.110
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.